Connect with LRI:
Facebook
Twitter
YouTube
Change.org

Lupus Clinical Trials

New Medical Therapies™

Pleural Diseases

Patient Medical Areas

July 15, 2002

Positive results were reported from a phase I/II trial of NicOx's NCX 950, an inhaled nitric oxide-donating drug for respiratory diseases. The randomized, double-blind, placebo-controlled trial was conducted in Switzerland and included 24 healthy subjects. The study was designed to compare treatment with an inhaled formulation of NCX 950 to treatment with salbutamol sulphate and placebo. Results indicated that NCX 950 was safe and well tolerated. Furthermore, data showed equipotency for NCX 950 in terms of bronchodilation and a faster onset of action compared to salbutamol.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.